

Contents lists available at ScienceDirect

# American Journal of Emergency Medicine

journal homepage: www.elsevier.com/locate/ajem

# Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis



Qingsu Lan<sup>a,b,c,1</sup>, Fengchao Wu<sup>a,1</sup>, Bing Han<sup>a,b,c</sup>, Lanhu Ma<sup>a</sup>, Junxian Han<sup>a</sup>, Yali Yao<sup>b,c,\*</sup>

<sup>a</sup> The First Clinical Medical College, Lanzhou University, Lanzhou, China

<sup>b</sup> Department of Heart Center, The First Hospital of Lanzhou University, Lanzhou, China

<sup>c</sup> Key Laboratory of Cardiovascular Diseases of Gansu Province, Lanzhou, China

#### ARTICLE INFO

Article history: Received 4 July 2021 Received in revised form 10 August 2021 Accepted 10 August 2021

*Keywords:* Atrial fibrillation Rapid ventricular rate Diltiazem Metoprolol

#### ABSTRACT

*Background:* Intravenous diltiazem and metoprolol are both commonly used to treat atrial fibrillation (AF) with rapid ventricular rate (RVR) in the emergency department (ED), but the advantages and disadvantages of these drugs cannot be verified. This meta-analysis aimed to assess the efficacy and safety of intravenous diltiazem versus metoprolol for AF with RVR.

*Method:* We systematically searched PubMed, Web of Science, Embase, Cochrane library, the China National Knowledge Infrastructure (CNKI), Wanfang, China Biology Medicine disc (CBM) and the WeiPu (VIP). Metaanalysis was performed using weighted mean difference (WMD), relative risk (RR) and 95% confidence interval (CI). Statistical analysis was performed using Review Manager 5.4.1.

*Results:* Seventeen studies involving 1214 patients in nine randomized controlled trials (RCTs) and eight cohort studies were included in meta-analysis, including 643 patients in the intravenous diltiazem group and 571 patients group in the intravenous metoprolol. The results of the meta-analysis showed that compared with intravenous metoprolol, intravenous diltiazem was found higher efficacy (RR = 1.11; 95% CI = 1.06 to 1.16, p < 0.00001), shorter average onset time (RR = -1.13; 95% CI = -1.97 to -0.28, p = 0.009), lower ventricular rate (RR = -9.48; 95% CI = -12.13 to -6.82, p < 0.00001), less impact on systolic blood pressure (WMD = 3.76; 95% CI: 0.20 to 7.33, P = 0.04), and no significant difference in adverse events (RR = 0.80, 95% CI = 0.55 to 1.14, P = 0.22) and diastolic blood pressure (WMD = -1.20; 95% CI: -3.43 to 1.04, P = 0.29) was found between intravenous diltiazem and metoprolol.

*Conclusion:* Intravenous diltiazem has higher efficacy, shorter average onset time, lower ventricular rate, less impact on blood pressure, and with no increase in adverse events compared to intravenous metoprolol.

© 2021 Published by Elsevier Inc.

#### 1. Introduction

Atrial fibrillation(AF) is the most common arrhythmia [1], and it is also the most commonly encountered cardiac dysrhythmia in emergency department (ED) [2]. With the aging of the population and the improvement of average age, the incidence rate of AF is increasing year by year. The incidence rate of AF has increased three times in the past 50 years [3]. The prevalence of AF in China in 2018 is 0.71%, and the incidence rate of elderly people over 75-year-old is 2.35% [4].

E-mail address: yaoyalifs@163.com (Y. Yao).

<sup>1</sup> These authors contributed equally to this work.

Nowadays the high incidence of AF is rising markedly, which has brought heavy financial burden to the world.

AF can cause asymptomatic or present with a wide spectrum of symptoms, including fatigue, palpitations, dyspnea, hypotension, and syncope, the most serious complication is stroke [5]. AF with rapid ventricular response (RVR) is defined as heart rate  $\geq 120$  beats per minute (bpm), and the use of drugs for rate or rhythm control is the option for management of AF in ED if patients who are hemodynamic stability [6]. Recommended by the plenty of guides, intravenous beta blockers or non-dihydropyridine calcium channel blocker can slow ventricular heart rate in the acute setting in patients without pre-excitation [7,8], however, there is no preference between them. Therefore, the main purpose of this meta-analysis was to provide evidence-based medicine for choosing the most appropriate drug to terminate the attack when patients with AF with RVR present to the ED.

<sup>\*</sup> Corresponding author at: No. 1 Donggang West Road, Chengguan District, Lanzhou, Gansu 730000, China.

# 2. Materials and methods

#### 2.1. Search strategy

PubMed, Embase, Web of Science, Cochrane library, the China National Knowledge Infrastructure (CNKI), China Biology Medicine disc (CBM), Wanfang, and the WeiPu (VIP) were systematically searched before June 2021. The main search terms were "Atrial Fibrillation", "Atrial Fibrillation\*", "Fibrillation\*, Atrial", "Auricular Fibrillation\*", "Fibrillation\*, Auricular", "Persistent Atrial Fibrillation", "Atrial Fibrillation\*, Persistent", "Fibrillation", Persistent Atrial", "Persistent Atrial Fibrillation", "Familial Atrial Fibrillation", "Atrial Fibrillation", Familial", "Familial Atrial Fibrillation\*", "Fibrillation\*, Familial Atrial", "Paroxysmal Atrial Fibrillation\*", "Atrial Fibrillation\*, Paroxysmal", "Fibrillation\*, Paroxysmal Atrial", "Diltiazem", "Cardil", "Cardizem", "CRD-401", "CRD 401", "CRD401", "Tiazac", "Dilacor XR", "Dilren", "Diltiazem Hydrochloride", "Diltiazem Malate", "Dilzem", "Aldizem", "Dilacor", "Metoprolol", "Toprol", "Betaloc", "Betaloc-Astra", "Betaloc Astra", "Betalok", "CGP-2175", "CGP 2175", "CGP2175", "H 93-26", "H 93 26", "H 932", "Metoprolol Tartrate", "Seloken", "Spesicor", "Spesikor", "Metoprolol Succi-nate", "Metoprolol CR-XL", "Metoprolol CR XL", "Toprol-XL", "Toprol XL", "Beloc-Duriles", "Beloc Duriles" and "Lopressor". We used these terms alone or in combination for literature search. The languages, publication type, and regions were not limited. We also checked the articles' reference lists to identify additional relevant publications. Two investigators reviewed each title and abstract screening and full-text review. A third investigator adjudicated any disagreements.

## 2.2. Inclusion and exclusion criteria

The inclusion criteria were as follows: ① Participants: Patients with AF were definitely diagnosed according to electrocardiogram, RVR was defined as heart rate  $\geq$  120 bpm, and aged 18 years old or above; ② Intervention: The experimental group was treated with intravenous diltiazem; The control group was treated with intravenous metoprolol; ③ Outcome measures: efficacy, average onset time, ventricular rate, impact on blood pressure, and adverse events; ④ Study type: randomized controlled trials (RCTs) or non-randomized controlled trials (non-RCTs).

The exclusion criteria were as follows: ① duplicated publications; ② systematic reviews and/or meta-analysis, expert commentaries or review articles, and case reports; ③ Incomplete or wrong data.

#### 2.3. Data extraction and quality assessment

The data extracted include: (1) Basic information of the reviewed studies: author, year of publication and sample size; (2) Research objects: patient age, gender, number of male patients; (3) Intervention measures: the treatment method of experimental group and control group; (4) Outcomes: efficacy, average onset time, ventricular rate, impact on blood pressure, and adverse events. Two investigators independently evaluated the included studies, assessed the quality of the articles, a third party when disagreement occurred until consensus was reached, and cross checked the results finally. The Oxford quality scoring system (Jadad scale) was used to evaluate the quality of literature for RCTs. All RCTs were evaluated on the basis of five items: patient randomization, appropriateness of generating a randomized sequence, adequacy of double-blind procedure, description of double-blinding method, details of patient's exclusion and drop-out. The quality score ranged between 0 and 5. Studies with Jadad score  $\geq$  3 were regarded to be of high-quality with a low risk of bias, while studies with Jadad score  $\leq 2$  were regarded to be of low-quality with a high risk of bias, and the Newcastle-Ottawa Quality Assessment Scale (NOS) was used to assess the quality of the included non-RCTs, which consists of three domains: selection, comparability and outcomes. Scores ranging from 0 to 9, Studies that received a score of six or higher were considered high-quality studies. Related table was shown in Table 1.

#### 2.4. Statistical analysis

The results were presented as relative risks (RR) with 95% confidence interval (CI) for dichotomous outcomes, weighted mean difference (WMD) with 95% CI for continuous outcomes. All effect indicators were evaluated for heterogeneity. We used a fixed-effects model in the absence of heterogeneity ( $I^2 < 50\%$ ). Otherwise, a random-effects model was used. P < 0.05 was considered statistically significant. Subgroup and sensitivity analysis were performed to explore sources of potential heterogeneity between studies and to explore other potentially confounding factors. Statistical analyses were performed using Review Manager, version 5.4.1 (RevMan, The Cochrane Collaboration, Oxford, UK).

# 3. Results

## 3.1. Search results and reviewed literature

A total of 315 studies were retrieved according to the inclusion and exclusion criteria, and a total of seventeen articles [9-25] were included in the meta-analysis. There are 10 high-quality and 7 low-quality studies. Fig. 1 is the flow chart demonstrating the detailed selection process and identification.

# 3.2. Study characteristics

A total of seventeen studies were included, which involved a total of 1214 patients. Among them, there were 643 cases in the diltiazem group and 571 cases in the metoprolol group. Table 1 summarizes the characteristics of included studies.

#### 3.3. Meta-analysis results

## 3.3.1. Efficacy

Thirteen studies [9,11-15,17-23] including 869 patients reported the efficacy. We conducted a subgroup analysis according to time, however, we found obvious heterogeneity in 5-min efficacy, 10-min efficacy, and 30-min efficacy, then we conducted sensitivity analysis and found that Fromm [9] was the source of heterogeneity. After the Fromm 2015 study was removed, no significant heterogeneity was observed among the studies ( $I^2 = 0\%$ , P = 0.96), thus we applied the fixed-effect model for further investigation. The pooled results showed that intravenous diltiazem was superior to intravenous metoprolol (RR: 1.11, 95% CI: 1.06 to 1.16, P<0.00001), and the results showed that intravenous diltiazem was better than intravenous metoprolol in the efficacy at 30 min (RR: 1.13, 95% CI: 1.03 to 1.24, P = 0.007), 60 min (RR: 1.11, 95% CI: 1.01to 1.23, P = 0.03). No statistically significant difference was found between two groups at 5 min (RR: 1.13, 95% CI: 0.96 to 1.32, P = 0.14), 10 min (RR: 1.09, 95% CI: 0.96 to 1.22, P = 0.17), 90 min (RR: 1.09, 95% CI: 1.00 to 1.18, P = 0.05), 120 min (RR: 1.10, 95% CI: 0.99 to 1.22, P = 0.06, Fig. 2).

#### 3.3.2. Average onset time

Seven studies [10,17-21,25] including 411 patients reported the average onset time. No significant heterogeneity was observed among the studies ( $I^2 = 39\%$ , P = 0.15), thus the fixed-effect model was used for further investigation. The results showed that the average onset time of intravenous diltiazem was significantly shorter than that of

#### Table 1

Author	Year	Scale	Score	Number(T/C)	Diltiazem	Metoprolol	Gender (male/female)	Age
Demircan	2005	Jadad	5	20/20	0.25 mg/kg (maximum 25 mg)	0.15 mg/kg (maximum 10 mg)	22/18	NA
Ye Xianhua	2007	Jadad	2	37/35	10 mg (maximum 30 mg)	5 mg (maximum 15 mg)	46/26	71.3 $\pm$ 10.6/72.1 $\pm$ 10.1
Lin Bin	2007	Jadad	2	35/39	15 mg	5 mg (maximum 10-15 mg)	NA	NA
Kong Xianmei	2008	Jadad	2	20/20	0.25 mg/kg (maximum 20 mg)	0.15 mg/kg (maximum 10 mg)	22/18	$61 \pm 18$
Diao Hongying	2009	NOS	7	24/24	10 mg	5 mg	22/26	$57 \pm 11/58 \pm 12$
Zhang Renhan	2009	NOS	5	38/21	0.25 mg/kg	5 mg (maximum 20 mg)	NA	NA
Zhong Sigan	2010	Jadad	2	40/40	0.25 mg/kg	5 mg (maximum 15 mg)	45/35	$70.1 \pm 7.7$
Fan Shuxiong	2012	NOS	7	24/24	10-15 mg	5 mg	24/24	NA
Han Jian	2013	Jadad	2	34/34	10 mg	5 mg (maximum 10 mg)	41/27	$68.9 \pm 2.7/69.5 \pm 2.3$
Gao Yi	2013	Jadad	2	40/40	NA	NA	45/35	69 ± 3
Fromm	2015	Jadad	5	24/28	0.25 mg/kg (maximum 30 mg)	0.15 mg/kg (maximum 10 mg)	26/26	$66.2\pm13.4/69.5\pm14.8$
Hines	2016	NOS	8	55/45	NA	NA	51/49	$64.2\pm12.0/64.2\pm12.0$
Hirschy	2019	NOS	8	34/14	NA	NA	31/17	$67.7\pm18.6/64.9\pm20.6^{\rm a}$
Nuñez	2020	NOS	7	80/80	NA	NA	83/77	$65.9\pm18.1/66.7\pm16.6^{\rm a}$
Nicholson	2020	NOS	7	63/45	10 mg(maximum 25 mg)	2.5(maximum 5 mg)	55/43	$64 \pm 11/68 \pm 13$
Sun Junhua	2012	Jadad	4	43/43	0.25 mg/kg(maximum 30 mg)	5 mg	57/29	$69.25\pm6.38/69.30\pm6.25$
Hargrove	2021	NOS	8	32/19	NA	NA	21/30	62.2 + 13.9/62.9 + 13.2

<sup>a</sup> The original study only provided the Median and Inter-Quartile Range. After numerical conversion according to the method of Hozo etc. [26], the Mean ± Standard Deviation was obtained.



Fig. 1. Flow diagram of study searching and selection process.

	diltiazer	m	metop	rolol		Risk Ratio		Risk Ratio
Study or Subgroup	Events 1	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
1.1.1 5min								
Demircan 2005	12	20	7	20	0.8%	1.71 [0.85, 3.44]		
Fromm 2015	12	24	3	28	0.0%	4.67 [1.49, 14.62]		
Gao Yi 2013 Kong Vienmei 2009	20	40	25	40	2.9%	1.04 [0.75, 1.45]		
Lin Bin 2007	23	20	25	20	0.0%	1.00 [0.94, 3.00]		
Sun Junhua 2020	23	43	25	43	3.0%	1.03 [0.73, 1.43]		
Zhong Sigan 2010	26	40	25	40	2.9%	1.04 [0.75, 1.45]		
Subtotal (95% CI)		198		202	13.1%	1.13 [0.96, 1.32]		◆
Total events	127		115					
Heterogeneity: Chi <sup>2</sup> = 4.	48, df = 5 (	(P = 0.	48); l² = l	0%				
Test for overall effect: Z	= 1.49 (P =	= 0.14)	)					
1.1.2 10min								
Demircan 2005	15	20	12	20	1.4%	1.25 [0.81, 1.94]		
Fromm 2015 Kong Vienmei 2000	17	24	10	28	1 404	Not estimable		
Kong Xianmei 2008 Lin Bin 2007	10	20	12	20	1.4%	1.33 [0.88, 2.03]		
Sun Junhus 2020	29	42	24	12	2,470	1.04 [0.04, 1.30]		
Zhong Sigan 2010	32	40	34	40	3.6%	1 03 [0.03, 1.27]		_ <b>_</b>
Subtotal (95% CI)	02	158	0.	162	13.7%	1.09 [0.96, 1.22]		◆
Total events	127		120					-
Heterogeneity: Chi <sup>2</sup> = 1.	89, df = 4 (	(P = 0.	76); l² =	0%				
Test for overall effect: Z	= 1.37 (P =	= 0.17)	)					
1.1.3 30min		-		-				
Diao Hongying 2009	22	24	20	24	2.3%	1.10 [0.89, 1.36]		
Fromm 2015	23	24	13	28		Not estimable		
Gao Yi 2013	37	40	32	40	3.7%	1.16 [0.97, 1.38]		
HIRSCRY 2019	15	30	8	13	1.3%	0.81 [0.46, 1.42]		
Nicholeon 2020	32	62	16	39	2.0%	1.02 [0.00, 1.10]		
Sun Junhua 2020	38	43	35	43	4.0%	1 09 0 91 1 30		
Zhong Sigan 2010	37	40	32	40	3.7%	1 16 [0 97 1 38]		
Subtotal (95% CI)	0.	275	02	244	21.1%	1.13 [1.03, 1.24]		♦
Total events	216		178					
Heterogeneity: Chi <sup>2</sup> = 5.	68, df = 6 (	(P = 0.	46); l² = l	0%				
Test for overall effect: Z	= 2.69 (P =	= 0.007	7)					
1.1.4 60min								
Hines 2016	26	46	18	41	2.2%	1.29 [0.84, 1.98]		
Hirschy 2019	16	30	9	13	1.5%	0.77 [0.47, 1.26]		
Lin Bin 2007	32	35	35	39	3.8%	1.02 [0.88, 1.18]		
Nuriez 2020 Sun Junhua 2020	43	80 42	34	80	3.9%	1.20 [0.91, 1.75]		
Zhang Penhan 2020	28 28	40	10	43	4.270	1.00 [0.92, 1.27]		<u> </u>
Zhong Sigan 2010	37	40	33	40	3.8%	1.12 [0.95, 1.33]		
Subtotal (95% CI)	0.	312	00	277	22.1%	1.11 [1.01, 1.23]		◆
Total events	229		183					
Heterogeneity: Chi <sup>2</sup> = 4.	70, df = 6 (	(P = 0.	58); l² = l	0%				
Test for overall effect: Z	= 2.15 (P =	= 0.03)	)					
1.1.5 90min								
Gao Yi 2013 Lia Dia 2007	37	40	33	40	3.8%	1.12 [0.95, 1.33]		
Lin Bin 2007 Cup, luphua 2020	32	35	35	39	3.8%	1.02 [0.88, 1.18]		
Sun Junnua 2020 Zhong Gigon 2010	39 27	43	30	43	4.2%	1.08 [0.92, 1.27]		
Subtotal (95% CI)	57	158		162	15.6%	1.09 [1.00, 1.18]		•
Total events	145		137					
Heterogeneity: Chi <sup>2</sup> = 1.	01, df = 3 (	(P = 0.	80); l <sup>2</sup> = l	0%				
Test for overall effect: Z	= 2.00 (P =	= 0.05)	)					
1.1.6 120min								
Hines 2016	33	51	19	36	2.6%	1.23 [0.85, 1.77]		
Lin Bin 2007	32	35	35	39	3.8%	1.02 [0.88, 1.18]		T
Sun Junhua 2020 Zhana Qiaca 2010	39	43	36	43	4.2%	1.08 [0.92, 1.27]		T_
∠nong Sigan 2010 Subtotal (05% CN	37	40	33	40	3.8%	1.12 [0.95, 1.33]		
Total evente	1.44	109	100	108	14.4%	1.10 [0.99, 1.22]		<b>▼</b>
Heterogeneity: Chiž – 1	141 50 df-27	(P = 0	68): 123	0%				
Test for overall effect: 7	= 1.85 (P =	, – ບ. : 0 0 ຄາ	)	0.0				
. correction offerent effect. 2		0.00)						
Total (95% CI)	1	1270		1205	100.0%	1.11 [1.06, 1.16]		•
Total events	985		856					
Heterogeneity: Chi <sup>2</sup> = 19	9.44, df = 3	2 (P =	0.96); l²	= 0%				
Test for overall effect: Z	= 4.67 (P <	× 0.000	001)				0.1	Eavours (diltiazem) Eavours (metoprotol)
Test for subaroup differ	ences: Chi	i² = 0.8	62. df = 5	i (P = 0.	99), I <sup>2</sup> = 0 <sup>4</sup>	%		- area fangarand - arous functional

Fig. 2. Forest plot for the meta-analysis of efficacy.



Fig. 3. Forest plot for the meta-analysis of average onset time.

intravenous metoprolol (WMD: -1.13; 95% CI: -1.97 to -0.28, P = 0.009, Fig. 3).

investigation. No difference was found for incidence of adverse events (RR = 0.80,95% CI:0.55 to 1.14, P = 0.22, Fig. 7).

## 3.3.3. Decrease in ventricular rate

Twelve studies [9-11,15,16,18-24] including 755 patients reported decrease in ventricular rate. There was obvious heterogeneity in all subgroups ( $I^2 > 50\%$ ), thus the random-effect model was selected for further investigation. The pooled results showed that intravenous diltiazem was superior to intravenous metoprolol (WMD = -9.48; 95% CI: -12.13 to -6.82, P < 0.00001). The results showed that intravenous diltiazem was better than intravenous metoprolol in decrease in ventricular rate at 5 min (WMD = -10.15; 95% CI: -19.49 to -0.81, P = 0.03), 10 min (WMD = -13.98; 95% CI: -20.47 to -7.50, P < 0.0001), 15 min (WMD = -9.63; 95% CI: -16.77 to -2.48, P =0.008), 30 min (WMD = -11.56; 95% CI: -17.05 to -6.07, P < 0.0001), 60 min (WMD = -7.97; 95% CI: -14.36 to -1.58, P =0.01), 90 min (WMD = -6.90; 95% CI: -11.95 to -1.84, P = 0.008). However, no statistically significant difference was found between two treatments at 120 min (WMD = -5.31; 95% CI: -11.48 to 0.86, P = 0.09, Fig. 4).

#### 3.3.4. Systolic blood pressure

Three studies [11,16,22] including 160 patients reported systolic blood pressure. There was no obvious heterogeneity in all subgroups ( $I^2 = 19\%$ , P = 0.26), thus the fixed-effect model was selected for further investigation. The results showed that two treatments were not statistically significant in terms of systolic blood pressure at 5 min (WMD = 6.63; 95% Cl: -1.59 to 14.84, P = 0.11), 10 min (WMD = 6.43; 95% Cl: -1.53 to 14.38, P = 0.11), 30 min (WMD = -1.72; 95% Cl: -7.32 to 3.87, P = 0.55). However, intravenous metoprol can decrease the systolic blood pressure at 15 min compared to intravenous diltiazem (WMD = 9.42; 95% Cl: 1.53 to 17.32, P = 0.02, Fig. 5).

#### 3.3.5. Diastolic blood pressure

Three studies [11,16,22] including 160 patients reported diastolic blood pressure. There was no obvious heterogeneity in all subgroups ( $l^2 = 0\%, P = 0.56$ ), thus the fixed-effect model was selected for further investigation. The results showed that two treatments were no statistical significance in terms of diastolic blood pressure at 5 min (WMD = -0.84; 95% CI: -5.23 to 3.54, P = 0.71), 10 min (WMD = -1.45; 95% CI: -5.75 to 2.85, P = 0.51), 15 min (WMD = 0.61; 95% CI: -3.64 to 4.85, P = 0.78) and 30 min (WMD = -3.94; 95% CI: -9.07 to 1.18, P = 0.13, Fig. 6).

#### 3.3.6. Adverse events

Fifteen studies [9-12,14-23,25] including 411 patients reported adverse events, there was no significant heterogeneity among the studies ( $l^2 = 0\%$ , P = 0.86), thus the fixed-effect model was selected for further

# 4. Discussion

Our meta-analysis showed that intravenous diltiazem was more effective than intravenous metoprolol in controlling ventricular rate in patients with AF with RVR. The advantage of intravenous diltiazem was gradually revealed at 30 min, and no significant difference was found at 90 and 120 min after intravenous injection. In terms of the decrease in ventricular rate, we observed that intravenous diltiazem was more effective, which reflected that the ventricular rate was slowed down more obviously and the onset time of diltiazem was shorter. There was no significant difference in diastolic blood pressure and adverse events between intravenous diltiazem and metoprolol, but we found that intravenous metoprolol may reduce systolic blood pressure. Therefore, for emergency doctors, intravenous diltiazem can control the ventricular rate in patients with AF with RVR well in ED, intravenous diltiazem has more benefits and less adverse events.

The joint American Heart Association and American College of Cardiology guidelines recommend the initial bolus dose of intravenous diltiazem is 0.25 mg/kg actual body weight, while the intravenous dose of metoprolol is 2.5–5.0 mg [7]. Diltiazem is a non-dihydropyridine calcium channel blocker and belongs to class IV antiarrhythmic drugs. Reported half-lives for the elimination phase of diltiazem in healthy volunteers have ranged from 2 to 7 h (average about 4.5 h), however, its potent vasodilatory activity often lead to decreases in peripheral resistance and blood pressure, the main adverse events of diltiazem were as follows: vasodilatation (resulting in headache or flushing, and occasional hypotension) and depression of at nodal conduction, but adverse events occur in only 2% to 10% and are generally minor in nature [27]. Metoprolol is selective B1 receptor blockers, belonging to class II antiarrhythmic drugs, it can control ventricular rate in patients with AF by reducing sympathetic activity, its half-lives in healthy have ranged from 2 to 6 h [28]. Both metoprolol and diltiazem can slow atrioventricular nodal conduction, however, our results showed that the onset time of intravenous diltiazem was shorter than that of intravenous metoprolol.

The limitations of this study include: ① The sample size of the included studies are relatively small, which makes the statistical power relatively low that may affect the accuracy of the results; ② Some of the included studies did not explicitly mention the random sampling method, some studies did not mention the allocation concealment scheme, therefore, there might be selective bias and implementation bias in the trial design. ③ We observed significant heterogeneity across the studies, which decreases the robustness of the conclusions despite the use of the random-effects model. ④ Some of the included studies had retrospective designs, therefore, selection bias, recall bias, and other biases should be considered. ⑤ The difference of drug dosage between different studies.

American Journal of Emergency Medicine 51 (2022) 248-256

	di	ltiazem		me	etoprolo	1		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Demircan 2005	-48 15	18 45	20	-31 15	22.17	20	17%	-17 00 (-29 64 -4 36)	
Fromm 2015	-40.13	17.52	24	-30	20.95	24	1.9%	-19.00 [-29.93, -8.07]	
Gao Yi 2013	-34.7	19.1	24	-14.9	19.22	28	1.9%	-19.80 [-30.24, -9.36]	
Han Jian 2013	-28.89	17.86	40	-9.64	16.1	40	2.2%	-19.25 [-26.70, -11.80]	
Hargrove 2021	-20.6	10.9	34	-32.1	10.22	34	2.5%	11.50 [6.48, 16.52]	
Lin Bin 2007	-29.85	17.86	35	-28.69	16.07	39	2.2%	-1.16 [-8.93, 6.61]	
Sun Junhua 2020	-23.89	19.52	43	-12.73	16.89	43	2.2%	-11.16 [-18.88, -3.44]	
Ye Xiannua 2007 Zhong Gigon 2010	-21	25.00	37	-23	20.00	35	1.8%	2.00 [-9.82, 13.82]	
Subtotal (95% CI)	-28.89	17.80	297	-9.04	16.1	303	18.7%	-19.25 [-26.70, -11.80]	•
Heterogeneity: Tau <sup>2</sup> =	182.32: 0	chi² = 90.	.91. df:	= 8 (P <	0.00001	);   <sup>2</sup> = 9	1%	-10.10[-10.40,-0.01]	-
Test for overall effect:	Z = 2.13 (	P = 0.03)	)	- (					
3.1.2 10min									
Demircan 2005	-52.7	17.83	20	-36.95	21.94	20	1.7%	-15.75 [-28.14, -3.36]	
Diao Hongying 2009	-52	17	24	-35	20.3	24	1.9%	-17.00 [-27.59, -6.41]	
Fromm 2015	-38.8	19.9	24	-20.5	19.35	28	1.9%	-18.30 [-29.01, -7.59]	
_in Bin 2007	-43.97	16.99	35	-37.87	15.56	39	2.2%	-6.10 [-13.55, 1.35]	
3un Junhua 2020	-38.99	16.13	43	-20.73	16.22	43	2.3%	-18.26 [-25.10, -11.42]	
Ye Xianhua 2007	-33	24.64	37	-36	24.88	35	1.8%	3.00 [-8.44, 14.44]	
Zhong Sigan 2010	-43.01	16.99	40	-19.82	15.69	40	2.3%	-23.19 [-30.36, -16.02]	
Subtotal (95% CI)	62 26· Ck	viz - 01 0	- 1h 0	6 /P - 0	0021-18	- 72%	14.2%	-15.98 [-20.47, -7.50]	•
Fest for overall effect:	Z = 4.22 (	P < 0.00	01)	0 (F = 0	1.002), 1	- 72%			
3 1 3 15min									
Demircan 2005	-54	17.73	20	-39.7	20.36	20	1.8%	-14.30 [-26.132.47]	
Diao Hongying 2009	-53	16.52	24	-39	19.08	24	2.0%	-14.00 [-24.10, -3.90]	
Fromm 2015	-41.2	18.88	24	-24.6	20.83	28	1.9%	-16.60 [-27.40, -5.80]	
Hargrove 2021	-52.33	14.14	32	-44.21	15	19	2.2%	-8.12 [-16.46, 0.22]	
re Xianhua 2007	-43	24.25	37	-48	24.56	35	1.8%	5.00 [-6.28, 16.28]	_ <del></del>
Subtotal (95% CI)			137			126	9.6%	-9.63 [-16.77, -2.48]	•
Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	38.19; Ch 7 = 2.64 (	ni² = 9.51 P = 0.00:	,df=4 8)	l (P = 0.0	05); I <sup>2</sup> = (	58%			
			-,						
3.1.4 30min Diao Hongying 2000	-50	26.00	24	-46	10	24	1 706	-14.00 [-26.05 -1.05]	
Fromm 2015	-46.5	20.05	24	-40	20.53	24	2.0%	-19 90 (-29 55 -10 25)	
Gao Yi 2013	-48.32	16.91	40	-29.79	13.08	40	2.3%	-18.53 [-25.16, -11.90]	
Hargrove 2021	-54.81	14.65	32	-41.23	15.35	19	2.1%	-13.58 [-22.155.01]	
Hirschy 2019	-32.15	19.55	34	-21.99	18.81	14	1.8%	-10.16 [-22.00, 1.68]	
Lin Bin 2007	-49.28	16.91	35	-49.84	12.74	39	2.3%	0.56 [-6.32, 7.44]	+
Sun Junhua 2020	-44.4	16.02	43	-32.73	13.41	43	2.4%	-11.67 [-17.91, -5.43]	
Ye Xianhua 2007	-48	25.06	37	-52	24.27	35	1.8%	4.00 [-7.40, 15.40]	+
Zhong Sigan 2010	-48.32	16.91	40	-29.79	13.08	40	2.3%	-18.53 [-25.16, -11.90]	
Subtotal (95% CI)	10.06.04	oi≅ – 20.7	2 df -	0 /P - 0	00021-1	282 2 - 749	18.7%	-11.50 [-17.05, -0.07]	•
Test for overall effect:	Z = 4.13 (	P < 0.00	01)	0 (F = 0	.0002), 1	- 747	0		
3 1 5 60min									
Han Jian 2012	-40.6	10.07	24	-45.7	0 70	24		Not estimable	
Hardrove 2021	-40.0	14.14	34	-40.7	5.79	10	2106	-8 52 L17 07 0 02	
Hirschy 2019	-33.96	19.05	34	-25 90	16.93	14	1,9%	-7.97 [-18.91 2.97]	
Lin Bin 2007	-51.8	16.7	35	-50.58	12.71	39	2.3%	-1.22 [-8.04, 5.60]	_ <del>_</del>
Sun Junhua 2020	-47.97	17.61	43	-33.72	14.08	43	2.3%	-14.25 [-20.99, -7.51]	
Ye Xianhua 2007	-50	23.9	37	-54	24.27	35	1.8%	4.00 [-7.13, 15.13]	+
Zhang Renhan 2009	-58	18.62	38	-54	17.74	21	2.0%	-4.00 [-13.62, 5.62]	-+
Zhong Sigan 2010	-50.84	16.7	40	-30.53	13.06	40	2.3%	-20.31 [-26.88, -13.74]	
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	55 10 <sup>.</sup> Cł	ni² = 24 9	259 = 1b 91	6 (P = 0	0003).1	211 211=769	14.8%	-7.97 [-14.36, -1.58]	•
Test for overall effect:	Z= 2.44 (	P = 0.01)	)			,			
3.1.6 90min									
Gao Yi 2013	-52.04	16.64	40	-39.61	14.47	40	2.3%	-12.43 [-19.265.60]	
Hargrove 2021	-47.25	14.32	32	-47.06	15	19	2.1%	-0.19 [-8.56, 8.18]	- <del> -</del>
Lin Bin 2007	-53	16.64	35	-49.66	14.24	39	2.3%	-3.34 [-10.44, 3.76]	-+
Bun Junhua 2020	-49.99	17.48	43	-38.39	15.54	43	2.3%	-11.60 [-18.59, -4.61]	
re Xianhua 2007	-52	23.58	37	-55	23.81	35	1.9%	3.00 [-7.95, 13.95]	
Zhong Sigan 2010	-52.04	16.64	40	-39.61	14.47	40	2.3%	-12.43 [-19.26, -5.60]	
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	24.24: Cł	ni² = 13.0	221 18, df =	5 (P = 0	1.02); I <sup>2</sup> =	<b>216</b> :62%	13.2%	-0.90 [-11.95, -1.84]	•
Test for overall effect:	Z = 2.67 (	P = 0.00	8)						
3.1.7 120min									
Hargrove 2021	-42.33	15.95	32	-45.71	15.81	19	2.1%	3.38 [-5.62, 12.38]	+
Lin Bin 2007	-54.94	16.78	35	-48.51	16.25	39	2.2%	-6.43 [-13.97, 1.11]	
Sun Junhua 2020	-53	17.12	43	-41.42	17.18	43	2.3%	-11.58 [-18.83, -4.33]	
Ye Xianhua 2007	-52	23	37	-55	23.81	35	1.9%	3.00 [-7.82, 13.82]	+
Zhong Sigan 2010	-54.98	16.72	40	-43.51	16.3	40	2.3%	-11.47 [-18.71, -4.23]	
Subtotal (95% CI)			187		000 17	176	10.7%	-5.31 [-11.48, 0.86]	
Heterogeneity: Tau <sup>2</sup> = Test for overall effect	31.51; Ch Z = 1.69 (	11* = 11.2 P = 0.091	:8,df= )	4 (P = 0	1.02); I* =	:05%			
- st.e. steran enett.	(	. 0.00,							
Fotal (95% CI)	67 27.04	18 - 224	1639	- 47 /0	~ 0.0007	1543	100.0%	-9.48 [-12.13, -6.82]	•
Test for overall effect:	7=6997	" - ∠∠4. P < ∩ ∩∩	. 99, UT: NN1)	- 47 (P	- 0.0000	///°≓	1 3 70		-100 -50 0 50 10
Test for subgroup diffi	0.50 ( erences: (	Chi <sup>2</sup> = 5 1	32. df=	: 6 (P = 4	1.50) P=	= 0%			Favours [diltiazem] Favours [metoprolol]

Fig. 4. Forest plot for the meta-analysis of decrease in ventricular rate.



Fig. 5. Forest plot for the meta-analysis of systolic blood pressure.



Fig. 6. Forest plot for the meta-analysis of diastolic blood pressure.

	diltiazem		metoprolol		Risk Ratio			Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI	_
Demircan 2005	0	20	0	20		Not estimable			
Diao Hongying 2009	0	24	0	24		Not estimable			
Fan Shuxiong 2012	0	24	0	24		Nut estimable			
Fromm 2015	2	24	5	28	9.8%	0.47 [0.10, 2.19]			
Gao Yi 2013	0	40	1	40	3.2%	0.33 [0.01, 7.95]		· · · · · · · · · · · · · · · · · · ·	
Hargrove 2021	19	32	11	19	29.2%	1.03 [0.64, 1.66]		+	
Hines 2016	2	55	2	45	4.7%	0.82 [0.12, 5.58]			
Hirschy 2019	1	34	0	14	1.5%	1.29 [0.06, 29.79]			
Kong Xianmei 2008	1	20	1	20	2.1%	1.00 [0.07, 14.90]			
Lin Bin 2007	1	35	0	38	1.0%	3.25 [0.14, 77.25]			
Nicholson 2020	9	63	7	45	17.3%	0.92 [0.37, 2.28]			
Sun Junhua 2020	3	43	4	43	8.5%	0.75 [0.18, 3.15]			
Ye Xianhua 2007	3	37	3	35	6.5%	0.95 [0.20, 4.38]			
Zhang Renhan 2009	3	38	6	21	16.3%	0.28 [0.08, 0.99]			
Zhong Sigan 2010	0	40	0	40		Not estimable			
Total (95% CI)		529		456	100.0%	0.80 [0.55, 1.14]		◆	
Total events	44		40						
Heterogeneity: Chi² = 5.48, df = 10 (P = 0.86); l² = 0%									
Test for overall effect: Z = 1.23 (P = 0.22)								U.1 1 10 100	
								Favours [unitiazerii] Favours [metoprotoi]	

Fig. 7. Forest plot for the meta-analysis of adverse events.

#### 5. Conclusion

Compared with intravenous metoprolol, intravenous diltiazem for AF with RVR has higher efficacy, shorter average onset time, lower ventricular rate, less impact on blood pressure, and no significant increase in adverse events.

#### Funding

None.

# Contributors

LQS and WFC conceived the research and set standards; LQS and WFC performed the research; LQS, WFC, and HB performed the statistical analysis; LQS and WFC wrote the manuscript; YYL and HB provided professional knowledge of treatment and made a final revision of the manuscript; all authors read and approved the final manuscript. LQS and WFC are the first authors of this paper.

# **Declaration of Competing Interest**

The authors declare no conflicts of interest.

#### Acknowledgements

None.

#### References

- [1] Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation. 2015;131(25):2176–84. https://doi.org/10.1161/circulationaha.114.014343.
- [2] Wakai A, O'Neill JO. Emergency management of atrial fibrillation. Postgrad Med J. 2003;79(932):313–9. https://doi.org/10.1136/pmj.79.932.313.
- [3] Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham heart study: a cohort study. Lancet. 2015;386(9989):154–62. https://doi.org/ 10.1016/s0140-6736(14)61774-8.
- [4] Wang Z, Chen Z, Wang X, Zhang L, Li S, Tian Y, et al. The disease burden of atrial fibrillation in China from a national cross-sectional survey. Am J Cardiol. 2018;122(5): 793–8. https://doi.org/10.1016/j.amjcard.2018.05.015.
- [5] Steger C, Pratter A, Martinek-Bregel M, Avanzini M, Valentin A, Slany J, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian stroke registry. Eur Heart J. 2004;25(19):1734–40. https://doi. org/10.1016/j.ehj.2004.06.030.

- [6] Long B, Robertson J, Koyfman A, Maliel K, Warix JR. Emergency medicine considerations in atrial fibrillation. Am J Emerg Med. 2018;36(6):1070–8. https://doi.org/ 10.1016/j.ajem.2018.01.066.
- [7] January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland Jr JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21): e1–76. https://doi.org/10.1016/j.jacc.2014.03.022.
- [8] Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. https://doi.org/10.1093/eurheartj/ ehw210.
- [9] Fromm C, Suau SJ, Cohen V, Likourezos A, Jellinek-Cohen S, Rose J, et al. Diltiazem vs. metoprolol in the Management of Atrial Fibrillation or flutter with rapid ventricular rate in the emergency department. J Emerg Med. 2015;49(2):175–82. https://doi. org/10.1016/j.jemermed.2015.01.014.
- [10] Hargrove KL, Robinson EE, Lusk KA, Hughes DW, Neff LA, Fowler AL. Comparison of sustained rate control in atrial fibrillation with rapid ventricular rate: metoprolol vs. Diltiazem. Am J Emerg Med. 2021;40:15–9. https://doi.org/10.1016/j.ajem.2020.11. 073.
- [11] Demircan C, Cikriklar HI, Engindeniz Z, Cebicci H, Atar N, Guler V, et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J. 2005;22(6):411–4. https:// doi.org/10.1136/emj.2003.012047.
- [12] Hines MC, Reed BN, Ivaturi V, Bontempo LJ, Bond MC, Hayes BD. Diltiazem versus metoprolol for rate control in atrial fibrillation with rapid ventricular response in the emergency department. Am J Health Syst Pharm. 2016;73(24):2068–76. https://doi.org/10.2146/ajhp160126.
- [13] Nuñez Cruz S, DeMott JM, Peksa GD, Slocum GW. Evaluation of the blood pressure effects of diltiazem versus metoprolol in the acute treatment of atrial fibrillation with rapid ventricular rate. Am J Emerg Med. 2020. https://doi.org/10.1016/j.ajem. 2020.10.003.
- [14] Nicholson J, Czosnowski Q, Flack T, Pang PS, Billups K. Hemodynamic comparison of intravenous push diltiazem versus metoprolol for atrial fibrillation rate control. Am J Emerg Med. 2020;38(9):1879–83. https://doi.org/10.1016/j.ajem.2020.06.034.
- [15] Hirschy R, Ackerbauer KA, Peksa GD, O'Donnell EP, DeMott JM. Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction. Am J Emerg Med. 2019;37(1):80–4. https://doi.org/ 10.1016/j.ajem.2018.04.062.
- [16] Ye XH, Yuan H, Ling F, Wang NF, ZHANG XW. A Compariative study on the efficacy and safety of intravenous diltiazem and metoprolol in elderly heart failure patients with rapid atrial fibrillation. Chin J Arterioscler. 2007;15(3):224–6.
- [17] Kong XM. Efficacy of intravenous diltiazem and metoprolol in the treatment of atrial fibrillation with rapid ventricular rate Chin. J Misdiagn. 2008;8(9):4556–7.
- [18] Sun JH, Gao S. Effect of intravenous diltiazem and metoprolol on patients with atrial fibrillation with rapid ventricular rate. Clin Res. 2020;28(2):83–5.
- [19] Zhong SG, Chen AW, Peng N. Contrasting the effectiveness of metoprolol and Diltiatem in rapid atrial fibrillation just by intravenous injection. Int Med Health Guid News. 2010;16(2):206–8.
- [20] Lin B, Zhang Y, Dai HY. Therapeutic efficacy of metoprolol and diltiazem on the treatment of rapid atrial fibrillation. Chin J Cardiovasc Rehabil Med. 2007;16(1):69–71.
- [21] Gao Y. A study on the efficacy of intravenous diltiazem and metoprolol on in elderly heart failure with rapid atrial fibrillation. Chin J Med Guide. 2013;15(1):125.
- [22] Diao HY, Liu B, Chen HB, Shi YF, Wang LJ. Comparison of the effectiveness of intravenous diltiazem and metoprolol in controlling the rapid ventricular rate in patients with atrial fibrillation. Chin | Emerg Med. 2009;18(10):1805–7.

- [23] Zhang RH, Zhang WC, Liu LP, Wang F. Emergency treatment of rapid atrial fibrillation and retrospective analysis of 1 82 cases. Chin J Med Guide. 2009;11(6):895–6.
  [24] Han J. The compared of the effect of metoprolol, diltiazem and Cedilanid for rapid atrial fibrillation. China Mod Med. 2013;20(10):83–4.
- [25] Fan SX. Atrium to shiver 112 example treament observation. Chin Manipul Qi Gong Ther. 2011;2(6):136-7.
- [26] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. https://doi.org/10.1186/1471-2288-5-13.
- [27 Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1985;29(5):387–454. https://doi.org/10.2165/ 00003495-198529050-00001.
- [28] Koch-Weser J. Drug therapy: metoprolol. N Engl J Med. 1979;301(13):698–703. https://doi.org/10.1056/nejm197909273011306.